Literature DB >> 16720498

Increased levels of BAL cysteinyl leukotrienesinacute [corrected] RSV bronchiolitis.

Chang Keun Kim1, Ji Yeon Koh, Tae Hee Han, Do Kyun Kim, Beyong Il Kim, Young Yull Koh.   

Abstract

BACKGROUND: Cysteinyl leukotrienes (CysLTs), including LTC4, LTD4 and LTE4, are pivotal mediators in the pathophysiology of asthma. AIM: To determine whether CysLT levels are increased in the lower airways of children with respiratory syncytial virus (RSV) bronchiolitis, as they are in asthmatic children, and to investigate a possible heterogeneity in CysLT levels in children with RSV bronchiolitis.
METHODS: Bronchoalveolar lavage (BAL) fluids were obtained from children with acute RSV bronchiolitis (n = 20), from children with acute asthma who had no identifiable virus infection (n = 16) and from control subjects (n = 14). BAL cell counts and differentials were determined, and the concentrations of CysLTs were measured by ELISA.
RESULTS: CysLT levels in the asthma (70.6 +/- 52.7 pg/ml, p < 0.001) and bronchiolitis groups (21.9 +/- 23.3 pg/ml, p < 0.05) were significantly higher than in the control group (8.7 +/- 5.2 pg/ml). Among bronchiolitis subjects, the eosinophil-positive subgroup (n = 6) showed significantly higher CysLT levels (49.0 +/- 26.7 pg/ml, p = 0.001) than the control group, but this was not observed in the eosinophil-negative subgroup (n = 14, 10.3 +/- 6.3 pg/ml, p = 0.47).
CONCLUSION: CysLT levels are increased in the lower airways during RSV bronchiolitis, although their intensities are lower than those in acute asthma. Among bronchiolitis subjects, high CysLT producers could be distinguished from low CysLT producers by the presence of eosinophilia in BAL fluids, suggesting a pathophysiological heterogeneity in RSV bronchiolitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720498     DOI: 10.1080/08035250600554268

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.

Authors:  Junyan Han; Yi Jia; Katsuyuki Takeda; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

2.  Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection.

Authors:  Jun Kubota; Sho Takahashi; Takayuki Suzuki; Akira Ito; Naoe Akiyama; Noriko Takahata
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

3.  Eosinophil survival and apoptosis in health and disease.

Authors:  Yong Mean Park; Bruce S Bochner
Journal:  Allergy Asthma Immunol Res       Date:  2010-03-24       Impact factor: 5.764

Review 4.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

5.  Immune recovery following bronchiolitis is linked to a drop in cytokine and LTC4 levels.

Authors:  Beatriz Sastre; María Luz García-García; Cristina Calvo; Inmaculada Casas; José Manuel Rodrigo-Muñoz; José Antonio Cañas; Inés Mora; Victoria Del Pozo
Journal:  Pediatr Res       Date:  2019-10-10       Impact factor: 3.756

Review 6.  The cell biology of acute childhood respiratory disease: therapeutic implications.

Authors:  Gerald M Loughlin; Anne Moscona
Journal:  Pediatr Clin North Am       Date:  2006-10       Impact factor: 3.278

7.  Stimulus-selective regulation of human mast cell gene expression, degranulation and leukotriene production by fluticasone and salmeterol.

Authors:  Adriana Catalli; Victor Karpov; Levente E Erdos; Brian P Tancowny; Robert P Schleimer; Marianna Kulka
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

Review 8.  Molecular and cellular mechanisms in the viral exacerbation of asthma.

Authors:  Sharyn Tauro; Yung-Chang Su; Sandra Thomas; Jürgen Schwarze; Klaus I Matthaei; Dijana Townsend; Ljubov Simson; Ralph A Tripp; Suresh Mahalingam
Journal:  Microbes Infect       Date:  2008-08-13       Impact factor: 2.700

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.